/
Theravance Biopharma, Inc. ( we, our, Theravance Biopharma or the Company ) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States ( US ) Food and Drug Administration (the FDA ) approved YUPELRI (revefenacin) inhalation solution indi…
The business is unprofitable at the operating level (-3.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 66.9% YoY with margins expanding 69.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$110M
▲ +66.9% YoY
Net Income (TTM)
$115M
▲ +287.7% YoY
Op. Margin
1.23%
▲ +69.6pp YoY
ROIC
0.35%
▲ +14.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$269M
▲ +2109.8% YoY
Op. Cash Flow (TTM)
$269M
▲ +2168.0% YoY
Net Debt
-$354M
Net Cash Position
Cash & Equiv.
$395M
5Y CAGR: +8.4%
Continue Research